Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2026-01-31 @ 8:27 PM
Study NCT ID:
NCT06274294
Status:
RECRUITING
Last Update Posted:
2024-07-31
First Post:
2024-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC
Sponsor:
CMC Ambroise Paré
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Inflammatory Bowel Diseases | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Inflammatory Bowel Diseases | View |
| None | Crohn's disease | View |
| None | Ulcerative colitis | View |
| None | Infliximab / CT-P13 | View |
| None | Intravenous | View |
| None | Subcutaneous | View |
| None | Pharmacokinetics | View |
| None | Efficacy | View |
| None | Safety | View |
| None | AUC | View |
| None | Ctrough | View |
| None | Fecal calprotectin | View |
| None | Antibodies to infliximab | View |
| None | C-reactive protein | View |
| None | TSQM | View |
| None | IBD disability index | View |